Ramses Erdtmann

Prior to founding Biomea Fusion in 2017, Ramses and Tom built-up Point Sur Investors, a long-only biotech investment fund focused solely on innovative therapies. Ramses also worked together with Tom at Pharmacyclics, where he most recently served as the Executive Vice President of Corporate Affairs. Ramses helped grow the company from approximately 40 employees with a market cap of $40M in 2009 to 650 employees and a market cap of $21B in 2015, when the company merged with AbbVie, Inc. He was involved in the operational expansion of the company and oversaw various departments during the growth phase including Finance, HR, Legal, Communications, IR, Facilities, Events, and IT. Prior to joining Pharmacyclics, Inc., Ramses managed assets for US high net-worth equity investors and large European closed-end funds. Ramses began his career at Commerzbank AG in Germany, where he was an investment banker and portfolio manager for international clients. He earned the Diplom Kaufmann degree with distinction in Finance and Banking from the Westfaelische Wilhelms Universität of Muenster, Germany.